# Talabostat in Treating Patients With Metastatic Kidney Cancer

> **NCT00489710** · PHASE2 · WITHDRAWN · sponsor: **University of Nebraska**

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** talabostat mesylate
- **BIOLOGICAL:** enzyme inhibitor therapy
- **DIAGNOSTIC_TEST:** flow cytometry
- **DIAGNOSTIC_TEST:** laboratory biomarker analysis
- **BIOLOGICAL:** non-specific immune-modulator therapy

## Key facts

- **NCT ID:** NCT00489710
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-12
- **Primary completion:** 2007-05-30
- **Final completion:** 2007-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** safety reasons
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489710, "Talabostat in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00489710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*